Info
Advances and Novel Treatment Options in Metastatic Melanoma
| Advances and Novel Treatment Options in Metastatic Melanoma |
| Autore | Facchiano Antonio |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 online resource (528 p.) |
| Soggetto topico | Medicine and Nursing |
| Soggetto non controllato |
ABT-737
acetazolamide acetylcholine adjuvant therapy amoeboid motility angiogenesis apoptosis arthralgia Bcl-2 family BCL2L10 biomarkers BRAF BRAF inhibitor BRAF inhibitors BRAF-mutant melanoma cancer cancer associated fibroblast cancer stem cells carbonic anhydrase cell therapy checkpoint inhibitor cholinergic system combined therapy ctDNA CXCL10 cyclopamine cytokines cytotoxicity diagnosis DOCK4 drug resistance essential oils exosomes extracellular vesicles FAK hedgehog HIPPO HuR immunity immunotherapy interferon invasion ipilimumab lactate dehydrogenase lipid metabolism liquid biopsy liver-directed-therapies machine learning MANS peptide MARCKS mechanism of action melanoma melanoma immune infiltrate melanoma markers melanoma metastasis melanoma PDX melanomagenesis metalloproteinases metastases metastasis metastatic dormancy metastatic therapy metastatic uveal melanoma (mUM) microenvironment microRNAs MITF ML258 motility mucosal melanoma muscarinic receptors n/a nanoparticles nicotinic receptors nivolumab OXPHOS patient stratification PD-1 pembrolizumab phosphorylation plasmacytoid dendritic cells prediction principal component analysis prognosis prognostication protein tyrosine phosphatase PTPs inhibitors Rac1 radiotherapy resistance rheumatoid arthritis sex-hormones sex/gender ShcD adaptor protein siRNA slow cycling phenotype small molecules SOCE STAT3 Support Vector Machine survival target therapy targeted therapy targeted-therapy therapeutic resistance therapy TLR TPC2 tumor microenvironment tumour microenvironment uveal melanoma (UM) WNT5A |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557612103321 |
Facchiano Antonio
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oncolytic Virus Immunotherapy
| Oncolytic Virus Immunotherapy |
| Autore | Marchini Antonio |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 online resource (366 p.) |
| Soggetto topico |
Clinical and internal medicine
Medicine and Nursing |
| Soggetto non controllato |
adenovirus
adoptive T cell therapy antigen-agnostic vaccination antitumor immune response arming biomarkers cancer cancer immune therapy cancer immunotherapy cancer therapy CAR T cell checkpoint inhibitor checkpoint inhibitors class I HLA clinical trials colorectal cancer combination therapy combinatory therapy CTLA-4 delivery DNA methyltransferase inhibitor (DNMTi) epigenetic silencing genetic modification glioblastoma HER2 herpes simplex virus HSV-1 immune checkpoint blockade immune checkpoint inhibitor immunoediting immunogenic cell death immunostimulatory immunosurveillance immunotherapy measles virus melanoma multi-stage n/a NDV newcastle disease virus oncogenic signaling oncolytic oncolytic adenovirus oncolytic virus oncolytic viruses pancreatic cancer pancreatic ductal adenocarcinoma parvovirus PD-1 PD-L1 personalized oncolyticvirotherapy RAS reovirus retargeted virus small molecule targeting tropism retargeting tumor tumor microenvironment type I interferon vaccination vector engineering vesicular stomatitis virus viral mimicry virotherapy αvβ6 integrin |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910566462203321 |
|
Marchini Antonio
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||